Table 1.
Outcomes over the whole INBUILD trial in subgroups by BMI at baseline
| BMI < 25 kg/m2 | BMI ≥ 25 to < 30 kg/m2 | BMI ≥ 30 kg/m2 | ||||
|---|---|---|---|---|---|---|
| Nintedanib (n = 90) |
Placebo (n = 98) |
Nintedanib (n = 130) |
Placebo (n = 112) |
Nintedanib (n = 111) |
Placebo (n = 121) |
|
| Acute exacerbation or death, n (%) with event | 12 (13.3) | 24 (24.5) | 18 (13.8) | 24 (21.4) | 16 (14.4) | 17 (14.0) |
| Hazard ratio (95% CI) | 0.52 (0.26, 1.04) | 0.66 (0.36, 1.21) | 0.92 (0.47, 1.83) | |||
| Treatment-by-subgroup interaction | p = 0.52 | |||||
| Progression of ILDa or death, n (%) with event | 44 (48.9) | 59 (60.2) | 48 (36.9) | 61 (54.5) | 42 (37.8) | 61 (50.4) |
| Hazard ratio (95% CI) | 0.74 (0.50, 1.10) | 0.65 (0.44, 0.94) | 0.64 (0.43, 0.95) | |||
| Treatment-by-subgroup interaction | p = 0.85 | |||||
Analyzed as time to first event
BMI body mass index, ILD interstitial lung disease
aAbsolute decline in forced vital capacity % predicted ≥ 10%